{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:41:46Z","timestamp":1778866906242,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81301118"],"award-info":[{"award-number":["81301118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.seizure.2017.07.005","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T13:16:37Z","timestamp":1500556597000},"page":"22-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy"],"prefix":"10.1016","volume":"51","author":[{"given":"Shenghui","family":"Mei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoqin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2017.07.005_bib0005","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"Loscher","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2017.07.005_bib0010","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","article-title":"Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling","volume":"65","author":"Jiang","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2017.07.005_bib0015","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/epi.13011","article-title":"Clinical significance of CYP2C9-status guided valproic acid therapy in children","volume":"56","author":"Budi","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.07.005_bib0020","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.seizure.2017.07.005_bib0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients","volume":"112","author":"Tan","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.seizure.2017.07.005_bib0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","article-title":"Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype","volume":"94","author":"Kiang","year":"2006","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.seizure.2017.07.005_bib0035","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","article-title":"Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"68","author":"Chu","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2017.07.005_bib0040","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/pgs.11.64","article-title":"Association of genetic variants in six candidate genes with valproic acid therapy optimization","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.seizure.2017.07.005_bib0045","first-page":"42","article-title":"An association between the FABP2 gene polymorphism and efficacy of valproates","volume":"107","author":"Aksenova","year":"2007","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"10.1016\/j.seizure.2017.07.005_bib0050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.09.001","article-title":"Effects of CYP3A4\/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy","volume":"117","author":"Wang","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2017.07.005_bib0055","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1755-5949.2012.00336.x","article-title":"ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients","volume":"18","author":"Qu","year":"2012","journal-title":"CNS Neurosci Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.seizure.2017.07.005_bib0060","first-page":"25","article-title":"Pharmacokinetics, drug interactions, and tolerability of valproate","volume":"37","author":"DeVane","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.seizure.2017.07.005_bib0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","article-title":"Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in Chinese children with epilepsy comedicated with lamotrigine","volume":"38","author":"Wang","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2017.07.005_bib0070","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.seizure.2017.07.005_bib0075","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat Rev: Neurosci"},{"key":"10.1016\/j.seizure.2017.07.005_bib0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eplepsyres.2015.04.015","article-title":"The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"114","author":"Sun","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2017.07.005_bib0085","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ejps.2009.09.017","article-title":"The influence of drug\u2013drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling","volume":"38","author":"Vucicevic","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.seizure.2017.07.005_bib0090","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1038\/srep04362","article-title":"Soybean greatly reduces valproic acid plasma concentrations: a food-drug interaction study","volume":"4","author":"Marahatta","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.seizure.2017.07.005_bib0095","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/FTD.0000000000000012","article-title":"Influence of uridine diphosphate glucuronosyltransferase 2B7-161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients","volume":"36","author":"Inoue","year":"2014","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2017.07.005_bib0100","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2217\/pgs.12.78","article-title":"Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid","volume":"13","author":"Chatzistefanidis","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.seizure.2017.07.005_bib0105","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.bcp.2011.08.004","article-title":"Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen","volume":"82","author":"Wang","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.seizure.2017.07.005_bib0110","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.clpt.6100324","article-title":"Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects","volume":"83","author":"Chung","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.seizure.2017.07.005_bib0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10038-003-0119-y","article-title":"Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity","volume":"49","author":"Iwai","year":"2004","journal-title":"J Hum Genet"},{"key":"10.1016\/j.seizure.2017.07.005_bib0120","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.tpj.6500210","article-title":"Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes","volume":"3","author":"Ho","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.seizure.2017.07.005_bib0125","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/FTD.0000000000000337","article-title":"Effects of UGT1A6 and GABRA1 on standardized valproic acid plasma concentrations and treatment effect in children with epilepsy in China","volume":"38","author":"Feng","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2017.07.005_bib0130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","article-title":"Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine","volume":"38","author":"Wang","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2017.07.005_bib0135","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.07.005_bib0140","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.07.005_bib0145","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1073\/pnas.98.2.581","article-title":"High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry","volume":"98","author":"Buetow","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.seizure.2017.07.005_bib0150","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00008571-199712000-00007","article-title":"Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications","volume":"7","author":"Ciotti","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.seizure.2017.07.005_bib0155","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/FPC.0b013e3283037fe4","article-title":"Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene","volume":"18","author":"Innocenti","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.seizure.2017.07.005_bib0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.seizure.2017.07.005_bib0165","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1158\/0008-5472.CAN-08-3708","article-title":"Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites","volume":"69","author":"Blevins-Primeau","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.seizure.2017.07.005_bib0170","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.50.2.259","article-title":"Developmental aspects of human hepatic drug glucuronidation in young children and adults","volume":"50","author":"Strassburg","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.seizure.2017.07.005_bib0175","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.247","article-title":"Urinary excretion of valproate metabolites in children and adolescents","volume":"21","author":"Reith","year":"2000","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.seizure.2017.07.005_bib0180","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.seizure.2017.07.005_bib0185","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/0006-2952(92)90324-C","article-title":"In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions","volume":"43","author":"Ponchaut","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.seizure.2017.07.005_bib0190","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/toxsci\/66.2.185","article-title":"Evaluation of child\/adult pharmacokinetic differences from a database derived from the therapeutic drug literature","volume":"66","author":"Ginsberg","year":"2002","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.seizure.2017.07.005_bib0195","first-page":"548","article-title":"Effect of maturation on drug disposition in pediatric patients","volume":"6","author":"Stewart","year":"1987","journal-title":"Clin Pharm"},{"key":"10.1016\/j.seizure.2017.07.005_bib0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1067\/mcp.2001.117367","article-title":"Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies","volume":"70","author":"Shintani","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.seizure.2017.07.005_bib0205","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00008571-200412000-00004","article-title":"Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism","volume":"14","author":"King","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.seizure.2017.07.005_bib0210","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.seizure.2017.07.005_bib0215","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00008571-200310000-00005","article-title":"Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6","volume":"13","author":"Kirchheiner","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.seizure.2017.07.005_bib0220","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/00008571-200311000-00005","article-title":"Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9)","volume":"13","author":"Kiyotani","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.seizure.2017.07.005_bib0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0009-9236(03)00090-0","article-title":"Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro","volume":"74","author":"Yoshida","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.seizure.2017.07.005_bib0230","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.seizure.2017.07.005_bib0235","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans","volume":"269","author":"de Morais","year":"1994","journal-title":"J Biol Chem"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117300699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117300699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:48:03Z","timestamp":1761011283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131117300699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":47,"alternative-id":["S1059131117300699"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2017.07.005","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2017.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}